VCA Stocks

Arcxis Biotechnologies, a privately held biomedical device firm, announced today that it has completed a Series A round of financing of nearly $2,250,000. The funds, invested by Claremont Creek Ventures, will enable Arcxis to accelerate development, testing, and commercialization of their products for rapid diagnostics, pathogen handling and sample preparation. By rapidly isolating, identifying and characterizing genes and proteins, Arcxis Biotechnologies’ products will enable faster, more accurate and more economical diagnosis of infectious diseases and other conditions marked by genetic and proteomic changes, such as cancer.